…syndrome (LQTS) is characterised by an abnormal prolongation of the QT interval on the surface electrocardiogram (ECG), which predisposes the myocardium to a specific form…

…on dialysis, where DOACs lack documentation or have only weak evidence. Venous thromboembolism when a DOAC cannot be used (interactions, cost, adherence, pregnancy after the…

…generally not recommended. If deemed necessary after careful individual benefit risk assessment by the prescribing physician: Initial dose : 60 mg single loading dose. Maintenance dose…

…despite maximally tolerated therapy. It is a prodrug activated predominantly in the liver by very long chain acyl CoA synthetase 1. This activating enzyme is…

…and unstable angina. The initial clinical distinction depends on symptoms, serial electrocardiography, and cardiac troponin findings. The default treatment after ACS, whether or not PCI…

…after the phosphorylation of a beta aspartate on the cytoplasmic face of the alpha subunit, thereby stabilizing the E2P conformation of the enzyme. By inhibiting…

…event while receiving maximally tolerated statin therapy, an LDL C goal below 1.0 mmol/L (<40 mg/dL) may be considered. The cited recommendations…

…one ASCVD risk equivalent who were receiving statins, inclisiran produced a further reduction in LDL C of approximately 50%. The effect was consistent in patients…

…reduction varies according to the statin, dose, and individual response. In general, statins reduce LDL C by approximately 30–55%; doubling the dose produces an…

…receiving maximally tolerated statin therapy, an LDL C goal below 1.0 mmol/L (<40 mg/dL) may be considered in the circumstances specified by…